Treatment Of Chronic Bronchitis Research Articles

A Controlled Evaluation of Bromhexine and Orciprenaline in the Treatment of Chronic Bronchitis

International Journal of Clinical PracticeVolume 25, Issue 12 p. 547-554 Clinical Trials A Controlled Evaluation of Bromhexine and Orciprenaline in the Treatment of Chronic Bronchitis D. McIntosh MB, CH.B, D. McIntosh MB, CH.B The Hounslow Chest ClinicSearch for more papers by this author D. McIntosh MB, CH.B, D. McIntosh MB, CH.B The Hounslow Chest ClinicSearch for more papers by this author First published: 01 December 1971 https://doi.org/10.1111/j.1742-1241.1971.tb09401.xRead the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Volume25, Issue12December 1971Pages 547-554 RelatedInformation

Endobronchial Polymyxin B: Experimental Observations in Chronic Bronchitis

Observations in three patients have shown that endobronchial administration of polymyxin B in 10 ml of saline through a transtracheal catheter achieves a wide bronchopulmonary distribution. The antibiotic was well tolerated when administered three times daily in doses of 300 μg to 1.0 mg. Concentrations of the antimicrobial reaching levels of 1.8 to 3.1 μg ml of expectorated sputum were achieved without adverse effects in a patient continuously for seven weeks with 1 mg of polymyxin B. Therapeutic concentrations of the drug in the sputum were maintained as long as 12 hours after endobronchial administration. The effectiveness of this technique in suppressing a chronic life-threatening bronchial infection with Pseudomonas aeruginosa is documented. The endobronchial approach in the treatment of chronic bronchitis is discussed.

Newer Drugs in the Treatment of Chronic Bronchitis

Newer Drugs in the Treatment of Chronic Bronchitis

Bronchopulmonary Lavage: New Techniques and Observations

A technique for bronchopulmonary lavage is presented as currently applied in the treatment of alveolar proteinosis and other bronchopulmonary disorders. This is a modification of a method previously published. 1 It permits repeated irrigation of a whole lung with liters of a saline solution containing acetylcysteine or heparin while the other lung is ventilated with 100 per cent oxygen. Clinical and laboratory observations during 25 lavages in seven patients are summarized. Bronchopulmonary lavage is effective in the treatment of alveolar proteinosis, may be helpful in the treatment of bronchial asthma, but does not appear useful in the treatment of chronic bronchitis. The technique presented should make bronchopulmonary lavage easier and safer.

Some Recent Advances in the Prevention and Treatment of Chronic Bronchitis and Related Disorders

Some Recent Advances in the Prevention and Treatment of Chronic Bronchitis and Related Disorders

Treatment of Chronic Bronchitis in General Practice with Methacycline*

Treatment of Chronic Bronchitis in General Practice with Methacycline*

Comparison of dimethylchlortetracycline (D.M.C.T.) withtetracycline in the treatment of chronic bronchitis: A report to the Research Committee of the British Tuberculosis Association

A comparison was made between tetracycline and dimethylchlortetracycline (D.M.C.T.)in the treatment of acute exacerbations of chronic bronchitis. The dosage used was as follows: tetracycline 500 mg. every 6 hours for 3 days, then 250 mg. every 6 hours for as long as the clinician considered desirable: D.M.C.T. 300 mg. every 6 hours followed by 150 mg. every 6 hours. 21 patients were treated with tetracycline and 25 with D.M.C.T. The results of treatment were similar in the two groups; but the incidence of side-effects was greater with D.M.C.T. Ten patients having this drug complained of nausea and 5 of vomiting, compared with 2 of nausea and 1 of vomiting in the tetracycline group.

Propicillin in the Treatment of Chronic Bronchitis

Propicillin in the Treatment of Chronic Bronchitis

Isoprenaline in the treatment of chronic bronchitis: A controlled trial of different methods of administration

Summary A controlled trial, in patients suffering from chronic bronchitis, shows that isoprenaline in a dose of 0·4 mg. delivered by a self-propelled aerosol device, Medihaler-iso Forte, gives an improvement in F.E.V. 1 on average 0·10 litre better and an improvement in V.C. 0·16 litre better than 3 minute continuous inhalation of 1 per cent. isoprenaline solution using a standard hospital nebulizer driven by an oxygen cylinder. Each of these results is statistically significant. The differences are not large or important clinically, but the much smaller dose given by the Medihaler reduces the chance of side effects and justifies rejection of the more standard methods of administration.

Comparison of Ampicillin and Tetracycline in Chronic Bronchitis

Ampicillin (6[D(-) a-aminophenylacetamido]penicil lanic acid; penbritin ), a new derivative of the penicillin nucleus, 6-aminopenicillanic acid, acts against many Gram-positive and Gram-negative organisms. In particular it has greater activity against Haemophilus influenzae than benzylpenicillin. Effective blood levels can be obtained after oral administration (Knudsen et al., 1961). These properties suggest that ampicillin may be valuable in the treatment of chronic bronchitis, and a trial was arranged to compare its efficacy with that of tetracycline.

The Treatment of Chronic Bronchitis and Obstructive Emphysema

The Treatment of Chronic Bronchitis and Obstructive Emphysema

DOUBLE‐BLIND CROSSOVER TRIAL OF BROMHEXINE (BISOLVON) IN THE TREATMENT OF CHRONIC BRONCHITIS

The results of a double-blind crossover trial of bromhexine (Bisolvon) in the treatment of chronic bronchitis are reported. Benefit was shown by statistically significant changes in the peak expiratory flow rate, ascultatory findings and sputum volume. Benefit was also demonstrated by changes in dyspnoea, sputum, consistency and ease of expectoration, but these were without statistical significance. A review of the literature together with the results of this trial suggest that, when adequate consideration is given to a number of therapeutic variables, Bisolvon will be effective medication for most patients with chronic bronchitis associated with thick, tenacious sputum.

Long-term tetracycline treatment of chronic bronchitis.

Cultures from patients with chronic bronchitis frequently grow hemophilus or pneumococcus. Thirty-two patients with well established chronic bronchitis were treated for 3 months at a time with 1.0 gm. daily of tetracycline, alternated with 3 months of indistinguishable placebos in a double blind study. About onethird as many exacerbations occurred during tetracycline treatment as during placebo treatment. In some patients, daily cough, sputum volume, and dyspnea were somewhat improved during tetracycline treatment. In individual patients there was a good correlation between eradication of pneumococcus and hemophilus and reduction of acute exacerbations. One patient had a fatal acute bronchitis due to an antibioticresistant staphylococcus during tetracycline therapy; otherwise, there was no evidence of replacement of normal flora during tetracycline treatment.

The Treatment of Chronic Bronchitis

The Treatment of Chronic Bronchitis

New Treatment for Chronic Bronchitis

New Treatment for Chronic Bronchitis

New Treatment for Chronic Bronchitis

New Treatment for Chronic Bronchitis

New Treatment for Chronic Bronchitis

New Treatment for Chronic Bronchitis

New Treatment for Chronic Bronchitis

New Treatment for Chronic Bronchitis

New Treatment for Chronic Bronchitis

New Treatment for Chronic Bronchitis

New Treatment for Chronic Bronchitis

New Treatment for Chronic Bronchitis